New hope for bladder cancer patients who Can't take standard chemo
NCT ID NCT06059547
Summary
This study is testing whether adding a new antibody drug called visugromab to standard immunotherapy helps shrink bladder tumors before surgery. It's for patients with muscle-invasive bladder cancer who cannot receive or refuse standard cisplatin chemotherapy. The goal is to see if this combination leads to better outcomes by reducing or eliminating cancer cells before the bladder is removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Città della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica
Roma, 00168, Italy
-
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University
Milan, 20132, Italy
Conditions
Explore the condition pages connected to this study.